Search
Elvitegravir
go.drugbank.com/drugs/DB09101ApprovedInvestigationalElvitegravir was first licensed from Japan Tobacco in 2008 and developed by Gilead Sciences. It was FDA approved on August 27, 2012. … Elvitegravir is a human immunodeficiency virus type 1 (HIV-1) integrase strand transfer inhibitor (INSTI) used for the treatment of HIV-1 infection in antiretroviral treatment-experienced adults.
Categories: Antivirals used in combination for the treatment of HIV infectionsInfluenza B virus B/Brisbane/60/2008 hemagglutinin antigen (formaldehyde inactivated)
go.drugbank.com/drugs/DB14385ApprovedInvestigationalWithdrawnInactivated virus cannot replicate, and therefore cannot cause disease from infection, even in immunocompromised individuals. … In contrast, live vaccines are produced from "wild-type" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques.
Mixtures: FluVaccinol Subunit Tetra Injektionssuspension in einer FertigspritzeTolevamer
go.drugbank.com/drugs/DB01344ApprovedIt may be taken orally or by rectum, as an enema, and functions as a potassium-binding resin in the intestines. … It is also an effective topical microbicide and spermicide, inhibiting the genital transfection of, among others, HIV.
Categories: Compounds used in a research, industrial, or household setting, Ion Exchange ResinsNafarelin
go.drugbank.com/drugs/DB00666ApprovedInvestigationalNafarelin has been used in the treatments of central precocious puberty and endometriosis. … Nafarelin is a potent synthetic agonist of gonadotropin-releasing hormone with 3-(2-naphthyl)-D-alanine substitution at residue 6.
Ruxolitinib
go.drugbank.com/drugs/DB08877ApprovedInvestigational[A229708] In 2014, it was approved for the treatment of polycythemia vera in adults who have an inadequate response to or are intolerant of [hydroxyurea] and in 2019, ruxolitinib was approved for use in … In phase II clinical trials, ruxolitinib improved chest computed tomography and improved recovery in patients with lymphopenia.
Brexanolone
go.drugbank.com/drugs/DB11859ApprovedInvestigationalprimary endpoints that compare success in the weaning of third-line agents and resolution of potentially life-threatening status epilepticus with brexanolone vs. placebo when added to standard-of-care … In particular, the use of brexanolone in treating PPD is surrounded with promise because it acts in part as a synthetic supplement for possible deficiencies in endogenous brexanolone (allopregnanolone)
Tioconazole
go.drugbank.com/drugs/DB01007ApprovedIn this way, tioconazole inhibits ergosterol synthesis, resulting in increased cellular permeability. … Tioconazole is an imidazole antifungal used to treat fungal and yeast infections. Topical formulations are used for ringworm, jock itch, athlete's foot, and tinea versicolor or "sun fungus".
Influenza A virus A/Kansas/14/2017 X-327 (H3N2) antigen (UV, formaldehyde inactivated)
go.drugbank.com/drugs/DB15520ApprovedWithdrawnInactivated virus cannot replicate, and therefore cannot cause disease from infection, even in immunocompromised individuals. … In contrast, live vaccines are produced from "wild-type" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques.
Mixtures: INFLUVAC TETRA, SUSPENSION FOR INJECTION IN PRE-FILLED SYRINGE 0.5 MLEliglustat
go.drugbank.com/drugs/DB09039ApprovedInvestigational[L41404,A7634] Eliglustat was approved by the FDA in August 2014 as an oral substrate reduction therapy for the first-line treatment of type 1 Gaucher disease. … In patients with Gaucher disease, the accumulation of glucosylceramide leads to the formation of Gaucher cells that infiltrate the liver, spleen, bone marrow and other organs.
Synonyms: N-[(1R,2R)-1-(2,3-Dihydro-1,4-benzodioxin-6-yl)-1-hydroxy-3-(1-pyrrolidinyl)-2-propanyl]octanamideNeisseria meningitidis serogroup B recombinant LP2086 B01 protein variant antigen
go.drugbank.com/drugs/DB10285ApprovedInvestigationalIt is contained in the suspension of Trumenba, which is a vaccine is composed of two recombinant lipidated factor H binding protein (fHBP) variants from N. meningitidis serogroup B, one from fHBP subfamily … Neisseria meningitidis serogroup b recombinant lp2086 b01 protein variant antigen is a sterile vaccine for intramuscular injection indicated for the active immunization to prevent invasive disease caused
Mixtures: TRUMENBA SUSPENSION FOR INJECTION IN SINGLE-DOSE PRE-FILLED SYRINGE 0.5ML